Financhill
Buy
80

CHGCY Quote, Financials, Valuation and Earnings

Last price:
$28.21
Seasonality move :
11.6%
Day range:
$28.00 - $29.40
52-week range:
$14.52 - $31.26
Dividend yield:
1.17%
P/E ratio:
37.53x
P/S ratio:
12.66x
P/B ratio:
7.28x
Volume:
79.8K
Avg. volume:
228.1K
1-year change:
77.31%
Market cap:
$92.8B
Revenue:
$7.7B
EPS (TTM):
$0.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CHGCY
Chugai Pharmaceutical
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$7.6B -- 1.82% -- $17.06
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CHGCY
Chugai Pharmaceutical
$28.21 -- $92.8B 37.53x $0.19 1.17% 12.66x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 25.20x
HLOSF
Healios KK
$2.25 -- $228.3M -- $0.00 0% 53.33x
PPTDF
PeptiDream
$13.53 -- $1.8B 21.21x $0.00 0% 4.80x
SOLTF
Nxera Pharma
$5.91 -- $531.3M -- $0.00 0% 2.96x
TAK
Takeda Pharmaceutical
$14.27 $17.06 $45.2B 33.52x $0.33 4.33% 1.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CHGCY
Chugai Pharmaceutical
-- -0.076 -- 5.95x
AMGXF
AnGes
-- 1.309 -- 1.10x
HLOSF
Healios KK
65.07% -2.492 34.39% 1.33x
PPTDF
PeptiDream
25.75% 0.548 6.45% 3.28x
SOLTF
Nxera Pharma
48.1% 1.902 78.18% 2.83x
TAK
Takeda Pharmaceutical
39.48% -0.250 73.42% 0.60x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CHGCY
Chugai Pharmaceutical
$1.3B $896.2M 21.98% 21.98% 47.37% $289.3M
AMGXF
AnGes
$259.5K -$13M -37.32% -22.74% -1559.14% --
HLOSF
Healios KK
$2.8M -$1.8M -55.94% -137.21% -24.5% -$4.8M
PPTDF
PeptiDream
$17.4M -$854.5K 24.02% 34.66% -1.5% $173.8M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M
TAK
Takeda Pharmaceutical
$4.8B -$147.2M 1.69% 2.85% 5.07% $2.1B

Chugai Pharmaceutical vs. Competitors

  • Which has Higher Returns CHGCY or AMGXF?

    AnGes has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -2947.39%. Chugai Pharmaceutical's return on equity of 21.98% beat AnGes's return on equity of -22.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHGCY
    Chugai Pharmaceutical
    69.55% $0.19 $12.7B
    AMGXF
    AnGes
    31.07% -$0.11 $158.3M
  • What do Analysts Say About CHGCY or AMGXF?

    Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than AnGes, analysts believe Chugai Pharmaceutical is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHGCY
    Chugai Pharmaceutical
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is CHGCY or AMGXF More Risky?

    Chugai Pharmaceutical has a beta of 0.771, which suggesting that the stock is 22.897% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CHGCY or AMGXF?

    Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.17%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHGCY or AMGXF?

    Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than AnGes quarterly revenues of $835.2K. Chugai Pharmaceutical's net income of $637.7M is higher than AnGes's net income of -$24.6M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 37.53x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 12.66x versus 25.20x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHGCY
    Chugai Pharmaceutical
    12.66x 37.53x $1.9B $637.7M
    AMGXF
    AnGes
    25.20x -- $835.2K -$24.6M
  • Which has Higher Returns CHGCY or HLOSF?

    Healios KK has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -107.23%. Chugai Pharmaceutical's return on equity of 21.98% beat Healios KK's return on equity of -137.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHGCY
    Chugai Pharmaceutical
    69.55% $0.19 $12.7B
    HLOSF
    Healios KK
    86.35% -$0.04 $57.8M
  • What do Analysts Say About CHGCY or HLOSF?

    Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHGCY
    Chugai Pharmaceutical
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is CHGCY or HLOSF More Risky?

    Chugai Pharmaceutical has a beta of 0.771, which suggesting that the stock is 22.897% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CHGCY or HLOSF?

    Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.17%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHGCY or HLOSF?

    Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than Healios KK quarterly revenues of $3.2M. Chugai Pharmaceutical's net income of $637.7M is higher than Healios KK's net income of -$3.4M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 37.53x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 12.66x versus 53.33x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHGCY
    Chugai Pharmaceutical
    12.66x 37.53x $1.9B $637.7M
    HLOSF
    Healios KK
    53.33x -- $3.2M -$3.4M
  • Which has Higher Returns CHGCY or PPTDF?

    PeptiDream has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -5.57%. Chugai Pharmaceutical's return on equity of 21.98% beat PeptiDream's return on equity of 34.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHGCY
    Chugai Pharmaceutical
    69.55% $0.19 $12.7B
    PPTDF
    PeptiDream
    47.13% -$0.02 $551.4M
  • What do Analysts Say About CHGCY or PPTDF?

    Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than PeptiDream, analysts believe Chugai Pharmaceutical is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHGCY
    Chugai Pharmaceutical
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is CHGCY or PPTDF More Risky?

    Chugai Pharmaceutical has a beta of 0.771, which suggesting that the stock is 22.897% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.312%.

  • Which is a Better Dividend Stock CHGCY or PPTDF?

    Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.17%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHGCY or PPTDF?

    Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Chugai Pharmaceutical's net income of $637.7M is higher than PeptiDream's net income of -$2.1M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 37.53x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 12.66x versus 4.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHGCY
    Chugai Pharmaceutical
    12.66x 37.53x $1.9B $637.7M
    PPTDF
    PeptiDream
    4.80x 21.21x $36.8M -$2.1M
  • Which has Higher Returns CHGCY or SOLTF?

    Nxera Pharma has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -11.44%. Chugai Pharmaceutical's return on equity of 21.98% beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHGCY
    Chugai Pharmaceutical
    69.55% $0.19 $12.7B
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About CHGCY or SOLTF?

    Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Chugai Pharmaceutical is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHGCY
    Chugai Pharmaceutical
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is CHGCY or SOLTF More Risky?

    Chugai Pharmaceutical has a beta of 0.771, which suggesting that the stock is 22.897% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.648%.

  • Which is a Better Dividend Stock CHGCY or SOLTF?

    Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.17%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHGCY or SOLTF?

    Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Chugai Pharmaceutical's net income of $637.7M is higher than Nxera Pharma's net income of -$5M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 37.53x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 12.66x versus 2.96x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHGCY
    Chugai Pharmaceutical
    12.66x 37.53x $1.9B $637.7M
    SOLTF
    Nxera Pharma
    2.96x -- $43.6M -$5M
  • Which has Higher Returns CHGCY or TAK?

    Takeda Pharmaceutical has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of 2.08%. Chugai Pharmaceutical's return on equity of 21.98% beat Takeda Pharmaceutical's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHGCY
    Chugai Pharmaceutical
    69.55% $0.19 $12.7B
    TAK
    Takeda Pharmaceutical
    63.56% $0.05 $78.1B
  • What do Analysts Say About CHGCY or TAK?

    Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.06 which suggests that it could grow by 20.25%. Given that Takeda Pharmaceutical has higher upside potential than Chugai Pharmaceutical, analysts believe Takeda Pharmaceutical is more attractive than Chugai Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHGCY
    Chugai Pharmaceutical
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is CHGCY or TAK More Risky?

    Chugai Pharmaceutical has a beta of 0.771, which suggesting that the stock is 22.897% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.114%.

  • Which is a Better Dividend Stock CHGCY or TAK?

    Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.17%. Takeda Pharmaceutical offers a yield of 4.33% to investors and pays a quarterly dividend of $0.33 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios CHGCY or TAK?

    Chugai Pharmaceutical quarterly revenues are $1.9B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.5B. Chugai Pharmaceutical's net income of $637.7M is higher than Takeda Pharmaceutical's net income of $156M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 37.53x while Takeda Pharmaceutical's PE ratio is 33.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 12.66x versus 1.51x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHGCY
    Chugai Pharmaceutical
    12.66x 37.53x $1.9B $637.7M
    TAK
    Takeda Pharmaceutical
    1.51x 33.52x $7.5B $156M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Sell
50
QDEL alert for May 10

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock